KORU Medical Systems reported Q4 and FY 2025 financial results with full year revenue growth of 22% to $41.1 million and a 57% improvement in net loss. The company initiated FY 2026 guidance projecting revenue of $47.5 - $50.0 million and positive adjusted EBITDA.
Key takeaways
Full year 2025 net revenues grew 22% to $41.1 million, with International Core revenue increasing 80%.
Full year 2025 net loss improved 57% to ($2.6) million, or ($0.06) per diluted share.
Full year 2025 Adjusted EBITDA was positive $0.6 million, compared to ($2.5) million in the prior year.
The company initiated FY 2026 guidance for net revenues of $47.5 - $50.0 million (15% - 22% growth) and positive adjusted EBITDA.
Ending cash balance was $8.9 million as of December 31, 2025, with annual cash usage of $0.7 million.